📈 Jumpstart Signal Watchlist — August 20, 2026

🏢 What they do: MeiraGTx Holdings plc is a clinical-stage genetic medicines company that develops gene therapies and other genetic medicine platforms for both rare and more common diseases. Its work includes programs in eye diseases, Parkinson’s disease, and radiation-induced dry mouth, along with its riboswitch technology for controlled delivery of biologic therapies.
- 🎯 Current $14.54 is 3% below 3yr high $14.97 · ⏳ SMA200 $9.39 (current price $14.54 is above) · 💰 Market Cap $1.4B
- MGTX shows decent technicals supported by positive sentiment.

💎 Quality (Q): 38/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 456% (>20%); PEG ratio 0.04 (<1.5).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (10.6%)
- 🔔 Strong above EMA50 (18.3%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 67 showing strength
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive (mixed coverage).
✅ FY2026 EPS Estimates for MeiraGTx Increased by HC Wainwright — MarketBeat.
🤖 HC Wainwright raised its FY2026 EPS estimate and kept a Buy rating with a $20 target, which is supportive for the stock. The note also references MeiraGTx’s strong quarterly beat, reinforcing bullish expectations.
✅ MeiraGTx (NASDAQ:MGTX) Upgraded by Wall Street Zen to "Buy" Rating — MarketBeat.
🤖 Wall Street Zen upgraded MeiraGTx to Buy after the company’s strong quarterly results. Analyst sentiment and the cited earnings beat both point to improved investor confidence.
❌ Alexandria Forbes Sells 62,000 Shares of MeiraGTx (NASDAQ:MGTX) Stock — MarketBeat.
🤖 CEO Alexandria Forbes sold 62,000 shares on August 18, which can weigh on sentiment because insider selling may signal caution. The report does not include any offsetting negative business development, so the stock impact is mainly modestly negative.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: The Manitowoc Company is a global manufacturer of engineered lifting solutions, mainly cranes and related equipment. Its products include mobile hydraulic cranes, tower cranes, crawler cranes, boom trucks, and associated aftermarket services and support.
- 🎯 Current $19.09 is 8% below 3yr high $20.87 · ⏳ SMA200 $13.14 (current price $19.09 is above) · 💰 Market Cap $688M
- MTW shows decent technicals supported by positive sentiment.

💎 Quality (Q): 45/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 875% (>20%); Low LT D/E 0.66 (<1.0); PEG ratio 0.04 (<1.5).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (9.8%)
- 🔔 Strong above EMA50 (23.8%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 67 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ The Manitowoc Company, Inc. Q2 2026 Earnings Call Highlights — Yahoo Finance / Motley Fool.
🤖 Manitowoc reported Q2 2026 earnings that beat expectations and highlighted July orders above $200 million, which signals stronger near-term demand. The article also notes the company raised its full-year outlook, a clear positive for the stock.
✅ Manitowoc Q2 2026 profit beats as stock jumps 32% — Investing.com.
🤖 The company posted adjusted EPS and revenue above estimates and lifted full-year guidance. The strong after-hours share reaction suggests investors viewed the report favorably.
✅ Manitowoc (NYSE:MTW) Hits New 52-Week High After Strong Earnings — MarketBeat.
🤖 This article says Manitowoc reached a new 52-week high after reporting better-than-expected quarterly earnings and stronger revenue. The stock move indicates the earnings beat was a meaningful catalyst for bullish sentiment.
🍭 Bonus (B): 0/10 — Construction Machinery

🏢 What they do: Bioventus Inc. is a global medical device company that develops and commercializes clinically proven, minimally invasive products to relieve pain and address musculoskeletal challenges by enhancing the body's natural healing process .
- 🎯 Current $14.33 is 6% below 3yr high $15.26 · ⏳ SMA200 $9.28 (current price $14.33 is above) · 💰 Market Cap $969M
- BVS shows decent technicals supported by positive sentiment.

💎 Quality (Q): 43/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 327% (>20%); ROE 24% (>15%); Near-high ROE setup (52wk high + ROE); PEG ratio 0.06 (<1.5).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (5.6%)
- 🔔 Strong above EMA50 (16.4%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 61 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Bioventus Reports Second Quarter Financial Results — GlobeNewswire.
🤖 Bioventus reported Q2 revenue growth, reaffirmed full-year 2026 guidance, and announced a review of strategic alternatives after receiving an unsolicited acquisition proposal. The guidance reaffirmation and takeover-interest angle are supportive for the stock, despite a modest revenue miss versus expectations.
✅ Bioventus Inc (BVS) (Q2 2026) Earnings Call Highlights — Yahoo Finance / GuruFocus News.
🤖 This recap highlights solid Q2 performance, including about 4% revenue growth and strong growth in the pain treatments business. The operational momentum and strategic review commentary are constructive for BVS.
✅ Bioventus (NASDAQ:BVS) Stock Price Expected to Rise ... — MarketBeat.
🤖 Canaccord Genuity raised its price target on Bioventus to $19 and maintained a Buy rating, signaling stronger analyst confidence. Higher price targets and a favorable consensus typically support the stock price.
🍭 Bonus (B): 0/10 — Surgical & Medical Instruments

🏢 What they do: South Bow Corporation operates crude oil pipeline infrastructure, including 4,900 kilometers of pipelines connecting Alberta supplies to U.S. Midwest and Gulf Coast refining markets, along with terminal storage and ancillary services.
- 🎯 Current $38.41 is 1% below 3yr high $38.67 · ⏳ SMA200 $31.83 (current price $38.41 is above) · 💰 Market Cap $8.0B
- SOBO shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (10.0% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 36% (>20%); ROE 16% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 4/20
- 📈 RSI at 66 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ South Bow (TSX:SOBO) On Strong Earnings And New Contracts While Fair Value Stays In View — Yahoo Finance.
🤖 This article highlights strong second-quarter earnings, an increased outlook, and 20-year contract commitments for the Prairie Connector and Liberty Bridge projects. Those developments improve revenue visibility and support a constructive view of the stock.
✅ South Bow Reports Second-quarter 2026 Results and Declares Dividend — Yahoo Finance / GlobeNewswire.
🤖 South Bow reported second-quarter 2026 results, returned capital to shareholders, and declared a quarterly dividend of $0.50 per share. The earnings release and dividend support a positive read-through for investors.
✅ South Bow Corp (SOBO) (Q2 2026) Earnings Call Highlights — Yahoo Finance.
🤖 The highlights emphasize secured 20-year customer commitments, which strengthen long-term cash flow visibility for the company. That kind of contract backing is favorable for the stock.
🍭 Bonus (B): 0/10 — Pipelines (Except Natural Gas)

🏢 What they do: Match Group operates a portfolio of online dating and relationship apps and websites, including Tinder, Hinge, Match, OkCupid, and Plenty of Fish. Its services are designed to help people make meaningful connections and meet potential partners through digital platforms.
- 🎯 Current $40.35 is 14% below 3yr high $46.87 · ⏳ SMA200 $34.13 (current price $40.35 is above) · 💰 Market Cap $9.3B
- MTCH shows decent technicals supported by positive sentiment.

💎 Quality (Q): 44/60
- 🏦 Low drawdown (11.6% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 43% (>20%); PEG ratio 0.33 (<1.5).
⏰ Entry (E): 4/20
- 🔔 Strong above EMA21 (5.2%)
- 📈 RSI at 60 showing strength
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive (mixed coverage).
✅ Match Group Announces Second Quarter Results — PR Newswire.
🤖 Match Group reported second-quarter results and said it was making progress in its product-led turnaround. The release also highlighted a declared cash dividend, which is generally supportive for shareholder returns.
✅ Match Group (NASDAQ:MTCH) Issues Earnings Results — MarketBeat.
🤖 The company beat adjusted EPS expectations, although revenue missed forecasts. The article also notes ongoing share repurchases and a quarterly dividend, both of which are constructive for the stock.
❌ Match Group (NASDAQ:MTCH) Stock Rating Lowered by Wall Street Zen — MarketBeat.
🤖 Wall Street Zen downgraded Match Group from buy to hold, which is a modest negative signal for sentiment. The article reflects a more cautious view even though the consensus rating remains roughly neutral to positive.
🍭 Bonus (B): 10/10 — Computer Programming & Data Processing (Technology sector)

🏢 What they do: American Healthcare REIT, Inc. (NYSE: AHR) is a real estate investment trust that acquires, owns, and operates a diversified portfolio of clinical healthcare properties, focusing primarily on senior housing communities, skilled nursing facilities, and outpatient medical buildings across the United States, the United Kingdom, and the Isle of Man.
- 🎯 Current $55.77 is 3% below 3yr high $57.72 · ⏳ SMA200 $50.18 (current price $55.77 is above) · 💰 Market Cap $10.9B
- AHR shows decent technicals supported by positive sentiment.

💎 Quality (Q): 55/60
- 🏦 Low drawdown (14.1% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 167% (>20%); Revenue growth 27% (>15%); Low LT D/E 0.00 (<1.0).
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive.
✅ American Healthcare REIT (NYSE:AHR) Updates FY 2026 Earnings Guidance — MarketBeat.
🤖 The company raised or reaffirmed FY 2026 EPS guidance to $2.15–$2.19, above analyst expectations, and also reported Q2 EPS of $0.16 versus the $0.14 consensus. That combination is supportive for the stock because it signals better-than-expected earnings momentum and improved full-year outlook.
✅ American Healthcare REIT (NYSE:AHR) Price Target Raised to $61.00 at Royal Bank of Canada — MarketBeat.
🤖 Royal Bank of Canada lifted its price target to $61 from $56 while keeping an outperform rating. A higher target from a major broker is typically constructive for sentiment and can support valuation.
⚪️ American Healthcare REIT Announces Leadership Appointments — Business Wire.
🤖 The company announced management changes, including Jeff Hanson becoming CEO and Gabe Willhite becoming President. This is likely neutral for the stock in the near term because it is a governance update rather than a direct operating or financial catalyst.
🍭 Bonus (B): 0/10 — REITs

🏢 What they do: ScanSource is a technology distributor that connects hardware, software, connectivity, and cloud solutions to channel partners and businesses. Its products and services include point-of-sale systems, barcode and data-capture equipment, networking, communications, physical security, payments, and related value-added services.
- 🎯 Current $56.39 is 4% below 3yr high $58.89 · ⏳ SMA200 $43.25 (current price $56.39 is above) · 💰 Market Cap $1.1B
- SCSC shows decent technicals supported by positive sentiment.

💎 Quality (Q): 54/60
- 🏦 Low drawdown (12.7% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 40% (>20%); Revenue growth 17% (>15%); Low LT D/E 0.38 (<1.0).
⏰ Entry (E): 3/20
- 🔔 Fresh SMA50 breakout
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive.
✅ ScanSource (NASDAQ:SCSC) Issues Quarterly Earnings Results — MarketBeat.
🤖 ScanSource reported adjusted EPS of $1.46 versus $1.14 expected and revenue of $953.11 million versus $814.35 million expected. Strong earnings beats are generally positive for the stock, even though the shares were slightly lower on the day.
✅ ScanSource (SCSC) Delivers Impressive Q2 Results, Raises Confidence With Strong Guidance — Yahoo Finance.
🤖 The company beat Wall Street on both revenue and adjusted EPS, and its full-year EBITDA guidance came in above analyst expectations. The upbeat results and outlook support a positive stock reaction.
⚪️ ScanSource faces earnings test after strong rally, downgrade — Investing.com.
🤖 This is a pre-earnings preview noting a recent rally and a downgrade, but it does not report actual results or new company developments. It offers limited direct fundamental impact by itself.
🍭 Bonus (B): 0/10 — Computers & Software - Wholesale

🏢 What they do: Concentra Group Holdings Parent, Inc. is a provider of occupational health services in the United States, focused on helping employers manage workplace injuries and employee health. Its services include occupational health centers, onsite employer clinics, telemedicine, workers’ compensation care, and other direct-to-employer health services.
- 🎯 Current $34.81 is 2% below 3yr high $35.53 · ⏳ SMA200 $24.30 (current price $34.81 is above) · 💰 Market Cap $4.4B
- CON shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (12.8% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 46% (>20%); ROE 42% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA50 (11.4%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 64 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Concentra Group Holdings Parent, Inc. Announces Results For Its Second Quarter Ended June 30, 2026 and Raises FY 2026 Guidance — Business Wire.
🤖 Concentra reported Q2 2026 revenue growth of 10.0%, net income growth of 46.5%, and Adjusted EBITDA growth of 22.5%, while also raising full-year 2026 guidance. The company also declared a cash dividend and announced a planned leadership transition, all of which are supportive for the stock.
✅ Concentra Group Holdings Parent (NYSE:CON) Sets New 1-Year High: Here’s Why — MarketBeat.
🤖 This article highlights strong recent momentum after Concentra’s earnings beat and mentions bullish analyst sentiment, including multiple Buy ratings and higher price targets. It is positive for the stock because it frames the shares as benefiting from better-than-expected results and favorable Street views.
✅ Concentra Group Holdings Parent (NYSE:CON) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says — MarketBeat.
🤖 The piece focuses on broadly positive analyst sentiment, with most analysts rating the stock a Buy and a consensus Moderate Buy outlook. That kind of coverage is typically supportive for the stock price.
🍭 Bonus (B): 0/10 — Specialty Outpatient Facilities